Literature DB >> 28674912

Liver Transplantation for Hepatocellular Carcinoma at Inonu University.

Cuneyt Kayaalp1, Volkan Ince2, Veysel Ersan2, Serdar Karakas2, Aysegul Sagir Kahraman2, Sezai Yilmaz2.   

Abstract

There is a great effort in the world to find a new drug in hepatocellular carcinoma (HCC) treatment. Turkey has a limited number of basic science studies to discover a new therapeutic drug for HCC. It seems that Turkey is distanced from the global drug discovery race and competition, however, Turkey has the advantage of a wide experience in living donor liver transplantation, like South Korea and Japan. Turkey can plan new studies on HCC, particularly with living donor liver transplantation. Neoadjuvant treatment methods before living donor liver transplantation for advanced tumors would be a good idea for study in Turkey. Because Inonu University has the busiest liver transplantation program in Turkey, the contribution of Inonu University to trials like this can improve the depth of the studies. To conclude, the Inonu University Liver Transplantation Institute has the busiest program in Turkey with 1,600 transplantations in eight years. The program is based on living donor liver transplantations (80%). Living donor liver transplantation for advanced HCC patients is our favorite topic to study.

Entities:  

Keywords:  Hepatocellular carcinoma; Liver transplantation; Living donation; Survival; Tumor staging

Year:  2017        PMID: 28674912     DOI: 10.1007/s12029-017-9965-2

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  2 in total

1.  Living donor liver transplantation for hepatocellular carcinoma.

Authors:  B Isik; V Ince; K Karabulut; C Kayaalp; S Yilmaz
Journal:  Transplant Proc       Date:  2012 Jul-Aug       Impact factor: 1.066

2.  Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients.

Authors:  Sami Akbulut; Cuneyt Kayaalp; Mehmet Yilmaz; Volkan Ince; Dincer Ozgor; Koray Karabulut; Cengiz Eris; Huseyin Ilksen Toprak; Cemalettin Aydin; Sezai Yilmaz
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

  2 in total
  2 in total

1.  Deceased donor liver transplantation from donors with central nervous system malignancy: Experience of the Inonu University.

Authors:  Volkan Ince; Veysel Ersan; Fatih Ozdemir; Bora Barut; Cemalettin Koc; Burak Isik; Cuneyt Kayaalp; Sezai Yilmaz
Journal:  North Clin Istanb       Date:  2017-10-25

2.  Are the criteria always right? Assessment of hepatocellular carcinoma cases in living zzm321990donor liver transplantation at a high-volume center

Authors:  Yücel Yankol; Gültekin Hoş; Turan Kanmaz; Nesimi Mecit; Yilmaz Çakaloğlu; Münci Kalayoğlu; Koray S Acarli
Journal:  Turk J Med Sci       Date:  2021-10-21       Impact factor: 0.973

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.